bullish
SK Bioscience (302440 KS): Operating Loss Widened in 3Q; What Lies Ahead
381 Views26 Oct 2024 13:59
SUMMARY
- In 3Q24, SK Bioscience (302440 KS) reported operating loss of KRW40B, compared with operating loss of KRW20B in 2Q24 mainly due to anemic gross profit margin and higher SG&A expenses.
- The company is expected to report sequentially better performance in 4Q24 on favorable product mix. Varicella vaccine export is expected to increase, while Sanofi vaccine distribution revenue is showing uptrend.
- Commencement of global phase 3 trial of SK Bioscience-Sanofi’s next-generation pneumococcal conjugate vaccine, PCV21 will lay the foundation for the company’s next level of growth.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SK Bioscience (302440 KS): Acquiring Majority Stake in IDT Biologika- A Step Toward ‘Globalization’30 Jun 2024
- SK Bioscience (302440 KS): Significantly Improved 3Q Result Benefitted From One-Time Payment28 Oct 2023
- SK Bioscience (302440 KS): Flu Vaccine Output Resumes; Next-Gen Typhoid Vaccine Is On Card14 Sep 2023
x